Michael L. Hawes

Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate

Charles E. Mowbray, Catherine Burt, Romuald Corbau et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 100 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Heterocyclic +12

Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency: The utility of animal models of disease in the toxicological evaluation of potential therapeutics

James Murray, Anne Marie Thompson, Allison Vitsky et al. · Molecular Genetics and Metabolism · 2014 · 52 citations · Full text

Minimal Effects on Immune Parameters Following Chronic Anti-TGF-β Monoclonal Antibody Administration to Normal Mice

Melanie C. Ruzek, Michael L. Hawes, Bruce M. Pratt et al. · Immunopharmacology and Immunotoxicology · 2003 · 52 citations

Use of Platelet-Rich Plasma Immediately After an Injury Did Not Improve Ligament Healing, and Increasing Platelet Concentrations Was Detrimental in an In Vivo Animal Model

Robert F. LaPrade, Laurie R. Goodrich, Jennifer N. Phillips et al. · The American Journal of Sports Medicine · 2017 · 50 citations

Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease

Michael L. Hawes, William R. Kennedy, M. W. O'CALLAGHAN et al. · Molecular Genetics and Metabolism · 2007 · 36 citations

Knockout Mouse, Pompe Disease, Enzyme Replacement Therapy +7